<DOC>
	<DOCNO>NCT00387335</DOCNO>
	<brief_summary>This phase II trial study well sunitinib work treat patient recurrent and/or metastatic head neck cancer . Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Recurrent and/or Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall response rate patient recurrent and/or metastatic squamous cell carcinoma head neck treat sunitinib malate . II . Determine toxicity drug patient . III . Determine feasibility administer drug patient ECOG performance status 2 ( cohort B ) . OUTLINE : This multicenter , cohort study . Patients assign one two cohort accord ECOG performance status ( ECOG 0-1 [ cohort A ] v ECOG 2 [ cohort B ] ) . Patients receive oral sunitinib malate daily day 1-28 . Courses repeat every 6 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically least 1 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Paranasal Sinus Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Criteria : Hemoglobin &gt; = 9 g/dL Histologically cytologically confirm squamous cell carcinoma head neck : Recurrent and/or metastatic disease Measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; = 20 mm conventional technique OR &gt; = 10 mm spiral CT scan No known brain metastasis Life expectancy &gt; = 2 month ECOG performance status ( PS ) 01 Karnofsky PS 70100 % ( patient cohort A ) ECOG PS 2 Karnofsky PS 6070 % ( patient cohort B ) WBC &gt; = 3,000/mm^3 Absolute neutrophil count &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Calcium = &lt; 12.0 mg/dL Bilirubin normal AST ALT = &lt; 2.5 time upper limit normal Creatinine normal OR creatinine clearance &gt; = 60 mL/min QTc &lt; 500 msec No New York Heart Association class III IV heart failure : Patients follow eligible provided New York Heart Association class II cardiac function baseline ECHO/MUGA : History class II heart failure asymptomatic treatment Prior anthracycline exposure Prior central thoracic radiation include heart radiotherapy port Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction compound similar chemical biological composition sunitinib malate No history serious ventricular arrhythmia ( i.e. , ventricular fibrillation ventricular tachycardia &gt; = 3 beat row ) No history significant ECG abnormalities No uncontrolled hypertension ( define systolic blood pressure [ BP ] &gt; = 140 mm Hg diastolic BP &gt; = 90 mm Hg ) No condition result inability take oral medication , include follow : Gastrointestinal tract disease result inability take oral medication requirement IV alimentation Active peptic ulcer disease No gastrostomy , jejunostomy , form enteral tubefeeding modality No serious nonhealing wound , ulcer , bone fracture No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day No cerebrovascular accident transient ischemic attack within past 12 month No myocardial infarction , cardiac arrhythmia , stable/unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within past 12 month No pulmonary embolism within past 12 month No preexist uncontrolled thyroid abnormality ( i.e. , inability maintain thyroid function within normal range medication ) No uncontrolled intercurrent illness , include either follow : Ongoing active infection Psychiatric illness social situation would limit compliance study requirement No two prior regimen recurrent metastatic disease : Prior chemotherapy part initial curative intent therapy ( e.g. , neoadjuvant , adjuvant , concurrent chemoradiotherapy ) allow count prior therapy recurrent metastatic disease At least 4 week since prior major surgery At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) recover At least 4 week since prior radiotherapy No prior treatment antiangiogenic agent ( e.g. , bevacizumab , sorafenib , pazopanib , AZD2171 , vatalanib , VEGF Trap ) No prior surgical procedure affect absorption At least 7 day since prior concurrent use CYP3A4 inhibitor , include follow : Azole antifungal ( e.g. , ketoconazole , itraconazole ) Verapamil Clarithromycin HIV protease inhibitor ( e.g. , indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) Erythromycin Delavirdine Diltiazem At least 12 day since prior concurrent CYP3A4 inducer , include follow : Rifampin Phenytoin Rifabutin Hypericum perforatum ( St. John 's wort ) Carbamazepine Efavirenz Phenobarbital Tipranavir No concurrent therapeutic dos coumarinderivative anticoagulant ( e.g. , warfarin ) : Concurrent dose = &lt; 2 mg warfarin daily prophylaxis thrombosis allow ; Concurrent low molecular weight heparin allow provide prothrombin time INR = &lt; 1.5 No concurrent investigational agent No concurrent agent proarrhythmic potential , include follow : Terfenadine Quinidine Procainamide Disopyramide Sotalol Probucol Bepridil Haloperidol Risperidone Indapamide Flecainide No concurrent anticancer agent therapies No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>